NM_025152.3:c.2T>C
Variant summary
Our verdict is Pathogenic. Variant got 11 ACMG points: 11P and 0B. PVS1_SupportingPM2PP5_Very_Strong
The NM_025152.3(NUBPL):āc.2T>Cā(p.Met1?) variant causes a start lost change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000314 in 1,402,386 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (ā ā ).
Frequency
Consequence
NM_025152.3 start_lost
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 11 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152088Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000104 AC: 14AN: 135226Hom.: 0 AF XY: 0.000107 AC XY: 8AN XY: 74808
GnomAD4 exome AF: 0.0000328 AC: 41AN: 1250180Hom.: 0 Cov.: 29 AF XY: 0.0000377 AC XY: 23AN XY: 610852
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152206Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74440
ClinVar
Submissions by phenotype
Mitochondrial complex 1 deficiency, nuclear type 21 Pathogenic:2
- -
The initiator codon variant p.M1T in NUBPL (NM_025152.3) has been reported to ClinVar as Likely Pathogenic. This variant is predicted to severely affect the synthesis of the NUBPL protein by disrupting the translation initiation start codon (ATG), resulting in a truncated or absent protein. The p.M1T variant has a GnomAD frequency of 0.01035 %. The p.M1T variant is a loss of function variant in the gene NUBPL, which is intolerant of Loss of Function variants. The variant is predicted to be damaging by both SIFT and PolyPhen2. The residue is conserved across species. The nucleotide change in NUBPL is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. For these reasons, this variant has been classified as Likely Pathogenic. In the absence of another reportable variant, the molecular diagnosis is not confirmed. -
Mitochondrial oxidative phosphorylation disorder Pathogenic:1
The p.Met1? (NM_025152.2 c.2T>C) variant in NUBPL has not been reported in indiv iduals with clinical features of mitochondrial complex I deficiency. This varian t has been identified in 0.14% (6/4298) of South Asian chromosomes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org; dbSNP rs567437692) . While its precise impact is not known, this variant is predicted to severely a ffect the synthesis of the NUBPL protein by disrupting the translation initiatio n start codon (ATG), resulting in a truncated or absent protein. Biallelic loss of function in the NUBPL gene has been associated with mitochondrial complex I d eficiency. In summary, although additional studies are required to fully establi sh a null effect, the p.Met1? variant is likely pathogenic for mitochondrial com plex I deficiency in an autosomal recessive manner based on its predicted functi onal impact. -
Mitochondrial complex I deficiency, nuclear type 1 Pathogenic:1
The start loss variant c.2T>C(p.Met1?) in NUBPL gene has not been reported previously as a pathogenic variant nor as a benign variant, to our knowledge. This variant is reported with the allele frequency (0.01%) in the gnomAD and novel in 1000 genome database. This variant has been reported to the ClinVar database as Likely Pathogenic. The p.Met1? variant is predicted to disrupt the initiation codon, and thus potentially may interfere with protein expression. This variant is predicted to cause loss of normal protein function through protein truncation. Loss of function variants have been previously reported to be disease causing. For these reasons, this variant has been classified as Likely Pathogenic. No significant variant in the NUBPL gene has been detected in the spouse. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at